CA3099922A1 - Compounds for treatment of pancreatic cancer - Google Patents

Compounds for treatment of pancreatic cancer Download PDF

Info

Publication number
CA3099922A1
CA3099922A1 CA3099922A CA3099922A CA3099922A1 CA 3099922 A1 CA3099922 A1 CA 3099922A1 CA 3099922 A CA3099922 A CA 3099922A CA 3099922 A CA3099922 A CA 3099922A CA 3099922 A1 CA3099922 A1 CA 3099922A1
Authority
CA
Canada
Prior art keywords
compound
another embodiment
alkyl
formula
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3099922A
Other languages
English (en)
French (fr)
Inventor
Wei Li
Duane D. Miller
Subhash Chauhan
Vivek Kumar Kashyap
Wang QINGHUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of CA3099922A1 publication Critical patent/CA3099922A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA3099922A 2018-05-15 2019-05-15 Compounds for treatment of pancreatic cancer Pending CA3099922A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671833P 2018-05-15 2018-05-15
US62/671,833 2018-05-15
PCT/US2019/032476 WO2019222392A1 (en) 2018-05-15 2019-05-15 Compounds for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
CA3099922A1 true CA3099922A1 (en) 2019-11-21

Family

ID=68541005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3099922A Pending CA3099922A1 (en) 2018-05-15 2019-05-15 Compounds for treatment of pancreatic cancer

Country Status (9)

Country Link
US (1) US20190374512A1 (cg-RX-API-DMAC7.html)
EP (1) EP3793548A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021523915A (cg-RX-API-DMAC7.html)
KR (1) KR20210021982A (cg-RX-API-DMAC7.html)
CN (1) CN112437664A (cg-RX-API-DMAC7.html)
AU (1) AU2019270091A1 (cg-RX-API-DMAC7.html)
CA (1) CA3099922A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020012292A (cg-RX-API-DMAC7.html)
WO (1) WO2019222392A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293661B2 (en) * 2020-04-03 2025-11-01 Veru Inc Sabizabulin for treating coronavirus infection
MX2023011719A (es) * 2021-04-05 2023-11-09 Veru Inc Métodos de tratamiento de la inflamación.
IL316387A (en) * 2022-04-28 2024-12-01 Veru Inc Polymorphs of [2-(1H-INDOL-3-YL)-1H-IMIDAZOL-4-YL](3,4,5-TRIMETHOXYPHENYL)methanone and its salts

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
UA105005C2 (uk) * 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
CA2791738C (en) * 2010-03-01 2020-06-09 Gtx, Inc. Aryl imidazolyl compounds for the treatment of cancer
MX336761B (es) * 2010-08-24 2016-01-29 Univ Tennessee Res Foundation Compuestos para el tratamiento de cancer.
CN105163584B (zh) * 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物

Also Published As

Publication number Publication date
JP2021523915A (ja) 2021-09-09
EP3793548A4 (en) 2022-03-09
KR20210021982A (ko) 2021-03-02
AU2019270091A1 (en) 2020-12-24
MX2020012292A (es) 2021-03-29
US20190374512A1 (en) 2019-12-12
CN112437664A (zh) 2021-03-02
EP3793548A1 (en) 2021-03-24
WO2019222392A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
KR102246652B1 (ko) 암 치료용 화합물
RU2581367C2 (ru) Соединения для лечения рака
AU2019270089B2 (en) Compounds for treatment of triple negative breast cancer and ovarian cancer
AU2013334874B2 (en) Combination therapies for the treatment of Alzheimer's disease and related disorders
US9447049B2 (en) Compounds for treatment of cancer
EP2608671B1 (en) Compounds for treatment of cancer
US11084811B2 (en) Compounds for treatment of cancer
KR20160054547A (ko) 비스테로이드성 항염증 약물 및 시그마 리셉터 리간드 조합들
KR20140117457A (ko) Rtk 억제제와 항에스트로겐의 조합물 및 암의 치료를 위한 그의 용도
BRPI0908675B1 (pt) Composto e composição farmacêutica
JP2019163314A (ja) 新規製剤
US20190374512A1 (en) Compounds for treatment of pancreatic cancer
JP2016536370A5 (cg-RX-API-DMAC7.html)
JP2014509608A (ja) 前立腺癌を治療するための、抗クラステリンオリゴヌクレオチドとhsp90阻害剤との併用
JP5587987B2 (ja) ニトリル誘導体ならびにそれらの薬学的使用および組成物
KR20180120765A (ko) 증식성 질환을 위한 조합 치료
HK40043322A (en) Compounds for treatment of pancreatic cancer
RU2776897C2 (ru) Соединения для лечения трижды негативного рака молочной железы и рака яичника
US11098017B2 (en) Compounds for treating disorders associated with abnormal steroidogenesis
HK40043706A (en) Compounds for treatment of triple negative breast cancer and ovarian cancer
HK1180965B (en) Compounds for treatment of cancer
HK1180965A (en) Compounds for treatment of cancer

Legal Events

Date Code Title Description
U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20241115

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20251117

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260105